Status and phase
Conditions
Treatments
About
Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer. The study is also being conducted to test if cemiplimab, alone or in combination, can reduce the size of your tumor by helping the immune system destroy the tumor.
Part 2 Cohorts D and E This study is being conducted to test the safety and pharmacokinetics of fianlimab and cemiplimab in patients with lung cancer. The study is also being conducted to test if fianlimab and cemiplimab, with or without chemotherapy, can reduce the size of your tumor by helping the immune system destroy the tumor.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Disease types under study:
ECOG (Eastern Cooperative Oncology Group) PS (Performance status) ≤1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature [eg, light housework or office work]). Note: Patients with ECOG PS >1 are ineligible.
Patients must have been born in Japan, and their biological parents and grandparents must all have been of Japanese origin
Willing and able to comply with clinic visits and study-related procedures
For Part 2, Cohorts D and E: Available tissue for retrospective testing using assay performed by a central laboratory, as specified in the study manual.
Key Exclusion Criteria:
Note: Other protocol defined inclusion/exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
145 participants in 6 patient groups
Loading...
Central trial contact
Clinical Trials Administrator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal